{"id":30304,"date":"2025-03-25T11:37:01","date_gmt":"2025-03-25T03:37:01","guid":{"rendered":"https:\/\/flcube.com\/?p=30304"},"modified":"2025-03-25T11:37:02","modified_gmt":"2025-03-25T03:37:02","slug":"shanghai-ark-biopharmaceuticals-ak0901-meets-phase-iii-endpoints-in-adhd-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30304","title":{"rendered":"Shanghai Ark Biopharmaceutical&#8217;s AK0901 Meets Phase III Endpoints in ADHD Trial"},"content":{"rendered":"\n<p>China&#8217;s Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study evaluating the efficacy, safety, and tolerability of its AK0901 in Chinese children aged 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). The trial successfully achieved both primary and key secondary endpoints, demonstrating statistical significance at all visiting time points compared to placebo.<\/p>\n\n\n\n<p><strong>Drug Profile and Mechanism<\/strong><br>AK0901, licensed from Swiss firm Commave Therapeutics, SA, is a novel methylphenidate-based drug combining immediate-release dexmethylphenidate (d-MPH) and the prodrug serdexmethylphenidate (SDX). It works by inhibiting the reuptake of dopamine and norepinephrine in the synaptic cleft, thereby enhancing neurotransmitter efficiency to alleviate ADHD symptoms. This combination makes AK0901 the first and only drug of its kind.<\/p>\n\n\n\n<p><strong>Clinical Trial Success<\/strong><br>The Phase III trial&#8217;s success marks a significant milestone for Shanghai Ark Biopharmaceutical. The positive results position AK0901 as a promising treatment option for ADHD, a chronic neurodevelopmental disorder characterized by attention deficits and\/or hyperactivity-impulsivity that often persists into adulthood.<\/p>\n\n\n\n<p><strong>Market Potential and Future Steps<\/strong><br>Approved in the US in March 2021, AK0901 represents the first new-generation methylphenidate drug in nearly two decades. Shanghai Ark Biopharmaceutical secured development and marketing rights through a USD 105.5 million licensing deal with Commave in December 2021. The company is likely to use these positive Phase III results to support future regulatory submissions and market expansion in China.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study&#8230;<\/p>\n","protected":false},"author":1,"featured_media":30305,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1443,17],"class_list":["post-30304","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ark-biopharmaceutical","tag-clinical-trial-results"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Ark Biopharmaceutical&#039;s AK0901 Meets Phase III Endpoints in ADHD Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study evaluating the efficacy, safety, and tolerability of its AK0901 in Chinese children aged 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). The trial successfully achieved both primary and key secondary endpoints, demonstrating statistical significance at all visiting time points compared to placebo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30304\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Ark Biopharmaceutical&#039;s AK0901 Meets Phase III Endpoints in ADHD Trial\" \/>\n<meta property=\"og:description\" content=\"China&#039;s Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study evaluating the efficacy, safety, and tolerability of its AK0901 in Chinese children aged 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). The trial successfully achieved both primary and key secondary endpoints, demonstrating statistical significance at all visiting time points compared to placebo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30304\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T03:37:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-25T03:37:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2504-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30304#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30304\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Ark Biopharmaceutical&#8217;s AK0901 Meets Phase III Endpoints in ADHD Trial\",\"datePublished\":\"2025-03-25T03:37:01+00:00\",\"dateModified\":\"2025-03-25T03:37:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30304\"},\"wordCount\":239,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30304#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2504-png.webp\",\"keywords\":[\"Ark Biopharmaceutical\",\"Clinical trial results\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30304#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30304\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30304\",\"name\":\"Shanghai Ark Biopharmaceutical's AK0901 Meets Phase III Endpoints in ADHD Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30304#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30304#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2504-png.webp\",\"datePublished\":\"2025-03-25T03:37:01+00:00\",\"dateModified\":\"2025-03-25T03:37:02+00:00\",\"description\":\"China's Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study evaluating the efficacy, safety, and tolerability of its AK0901 in Chinese children aged 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). The trial successfully achieved both primary and key secondary endpoints, demonstrating statistical significance at all visiting time points compared to placebo.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30304#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30304\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30304#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2504-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2504-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shanghai Ark Biopharmaceutical's AK0901 Meets Phase III Endpoints in ADHD Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30304#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Ark Biopharmaceutical&#8217;s AK0901 Meets Phase III Endpoints in ADHD Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Ark Biopharmaceutical's AK0901 Meets Phase III Endpoints in ADHD Trial - Insight, China&#039;s Pharmaceutical Industry","description":"China's Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study evaluating the efficacy, safety, and tolerability of its AK0901 in Chinese children aged 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). The trial successfully achieved both primary and key secondary endpoints, demonstrating statistical significance at all visiting time points compared to placebo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30304","og_locale":"en_US","og_type":"article","og_title":"Shanghai Ark Biopharmaceutical's AK0901 Meets Phase III Endpoints in ADHD Trial","og_description":"China's Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study evaluating the efficacy, safety, and tolerability of its AK0901 in Chinese children aged 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). The trial successfully achieved both primary and key secondary endpoints, demonstrating statistical significance at all visiting time points compared to placebo.","og_url":"https:\/\/flcube.com\/?p=30304","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-25T03:37:01+00:00","article_modified_time":"2025-03-25T03:37:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2504-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30304#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30304"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Ark Biopharmaceutical&#8217;s AK0901 Meets Phase III Endpoints in ADHD Trial","datePublished":"2025-03-25T03:37:01+00:00","dateModified":"2025-03-25T03:37:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30304"},"wordCount":239,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30304#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2504-png.webp","keywords":["Ark Biopharmaceutical","Clinical trial results"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30304#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30304","url":"https:\/\/flcube.com\/?p=30304","name":"Shanghai Ark Biopharmaceutical's AK0901 Meets Phase III Endpoints in ADHD Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30304#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30304#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2504-png.webp","datePublished":"2025-03-25T03:37:01+00:00","dateModified":"2025-03-25T03:37:02+00:00","description":"China's Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study evaluating the efficacy, safety, and tolerability of its AK0901 in Chinese children aged 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). The trial successfully achieved both primary and key secondary endpoints, demonstrating statistical significance at all visiting time points compared to placebo.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30304#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30304"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30304#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2504-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2504-png.webp","width":1080,"height":608,"caption":"Shanghai Ark Biopharmaceutical's AK0901 Meets Phase III Endpoints in ADHD Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30304#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Ark Biopharmaceutical&#8217;s AK0901 Meets Phase III Endpoints in ADHD Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2504-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30304"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30304\/revisions"}],"predecessor-version":[{"id":30306,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30304\/revisions\/30306"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30305"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}